A related commentary discusses this research highlighting that risankizumab was the eleventh biologic agent approved for psoriasis. Many factors impact the treatments selected for patients. These include patient weight, childbearing status, age, associated conditions such as psoriatic arthritis, comorbid diseases such as inflammatory bowel disease, lupus, and multiple sclerosis, concomitant infections such as hepatitis B or C or HIV, and risk factors for cardiovascular disease.
The results of this study however give us another highly effective, convenient therapy that will help many patients with psoriasis.